BCL2L1 and leukemia: Recent studies in leukemia have reported that miR-377 is capable of negatively regulating the expression of BCL-xL in resistant ABT-199 cells, as well as in a panel of lymphoid lines of B cells and primary chronic lymphocytic leukemia.